



## Geron to Present at Upcoming Investor Conferences

9/1/2022

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to present in-person at the following investor conferences in New York City:

- Morgan Stanley 20th Annual Global Healthcare Conference  
Fireside chat on Monday, September 12, 2022, at 5:25 p.m. ET
- H.C. Wainwright 24th Annual Global Investment Conference  
Corporate presentation on Tuesday, September 13, 2022, at 12:30 p.m. ET
- Baird 2022 Global Healthcare Conference  
Fireside chat on Wednesday, September 14, 2022, at 1:25 p.m. ET

A webcast of each fireside chat and corporate presentation will be available through the Investor Relations section of Geron's website under **Events**. Following each scheduled conference event, the related webcast will be archived and available for replay for a period of 30 days.

### About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in relapsed/refractory myelofibrosis.

View source version on **businesswire.com**: <https://www.businesswire.com/news/home/20220901005110/en/>

Aron Feingold

Investor and Media Relations

[investor@geron.com](mailto:investor@geron.com)

[media@geron.com](mailto:media@geron.com)

Source: Geron Corporation